Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2016-07-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Appendix 4C - June Quarterly 7 pages 588.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'June 2016 Quarterly Update and Appendix 4C' and contains detailed financial data including cash flow statements, operating cash flows, investing and financing activities, and reconciliation of cash. It reports quarterly financial performance and cash movements for Bioxyne Limited for the quarter ended 30 June 2016. The presence of an Appendix 4C, which is a standard quarterly report format for entities admitted on the basis of commitments, confirms this is a quarterly financial report. The document is over 10,000 characters, indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q4 2016
2016-07-27 English
Bioxyne Commences New Clinical Trial 2 pages 329.3KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 23 June 2016 from Bioxyne Limited, detailing the commencement of a new clinical trial for its proprietary probiotic product. It discusses the trial's design, purpose, and expected outcomes, but does not contain any financial data, regulatory filings, or detailed financial reports. The content is focused on a business update related to product development and marketing support rather than financial results or governance. The document length is 4509 characters, which is relatively short and reads like a press release or announcement rather than a detailed report. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other financial filing. It is also not a regulatory filing or certification. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2016-06-22 English
Directors Equity Based Incentives 3 pages 402.8KB
Board/Management Information Classification · 95% confidence The document is an announcement from Bioxyne Limited regarding equity-based incentive remuneration packages for its Executive Director and Non-Executive Directors. It details proposed options issuance subject to shareholder approval at the next general meeting. The document focuses on remuneration and equity incentives, not on financial results, audit, or management reports. It also mentions that shareholder approval will be sought at the next general meeting, indicating this is a notice or announcement rather than the actual meeting materials or voting results. This fits best under Board/Management Information (MANG) as it relates to changes in director remuneration and incentives, which is a management/board-related announcement. The document is over 5,000 characters and contains substantive detail about the incentive packages, not just a brief notice or regulatory filing. Therefore, the classification is MANG with high confidence.
2016-06-14 English
Change of Director's Interest Notice - George Cameron-Dow 3 pages 227.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of securities held before and after the change, the nature of the change, and dates. This is a report of personal share transactions by a company director, which fits the definition of 'Director's Dealing'. The document length is 4321 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, audit report, or any other category. Therefore, the correct classification is 'DIRS'.
2016-05-04 English
Change of Director's Interest Notice - Anthony Ho 2 pages 225.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the interest, and the value of the transaction. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing' filings. The document length is 3672 characters, which is consistent with a detailed notice but not a full financial report. Therefore, the correct classification is DIRS (Director's Dealing).
2016-05-04 English
Change of Director's Interest Notice - Patrick Ford 3 pages 226.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, the nature of the change (exercise of options), and the value of the transaction. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements, earnings data, or management commentary, so it is not an annual report, earnings release, or management report. It is specifically a Director's Dealing notice.
2016-05-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.